Novo Nordisk to apply Zosano's delivery system to Type II diabetes candidate; deal terminated
Zosano Pharma Inc. (transdermal drug delivery) granted Novo Nordisk AS exclusive worldwide rights to use its microneedle patch system in the development and commercialization of glucagon-like peptide-1 (GLP-1) analogues.
- Medical Devices
- Drug Delivery
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.